PD
MYGN icon

Point72 (DIFC)’s Myriad Genetics MYGN Stock Holding History

Point72 (DIFC)’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$32.2K Sell
4,460
-17,803
-80% -$106K ﹤0.01% 801
2025
Q2 		$118K Buy
22,263
+7,234
+48% +$42.7K ﹤0.01% 893
2025
Q1 		$133K Buy
15,029
+7,416
+97% +$89.1K 0.01% 1012
2024
Q4 		$104K Buy
7,613
+4,913
+182% +$90.7K ﹤0.01% 998
2024
Q3 		$74K Buy
2,700
+241
+10% +$6.52K ﹤0.01% 1025
2024
Q2 		$60.2K Buy
+2,459
New +$54K ﹤0.01% 1054

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 (DIFC)'s MYGN Position: Q3 2025 in Review

Point72 (DIFC) reduced its Myriad Genetics (MYGN) stake by 80% in Q3 2025, selling an estimated $106K and leaving 4,460 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #801.

Point72 (DIFC) first reported a position in MYGN in Q2 2024 and has held it in 6 quarters since. The position peaked at $133K in Q1 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Point72 (DIFC) held 4,460 shares of Myriad Genetics worth $32.2K as of Q3 2025.
  • Point72 (DIFC) sold 17,803 Myriad Genetics shares in Q3 2025, an estimated $106K.
  • Myriad Genetics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #801 holding.
  • Point72 (DIFC) first reported a position in Myriad Genetics in Q2 2024 and has held it in 6 quarters since.
  • Point72 (DIFC)'s Myriad Genetics position peaked at $133K in Q1 2025.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.